Biology subjects

Miller, G. W.

Publications and source records attributed to Miller, G. W..

3 recordsLinked to original sources

bioRxiv2018

Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens

BackgroundThe D3 receptor (D3R) has emerged as a promising pharmacotherapeutic target for the treatment of several diseases including schizophrenia, Parkinsons disease, and substance use disorders. However, studies investigating the modulatory impact of D3R antagonism on dopamine neurotransmission or the effects drugs of abuse have produced mixed results, in part because D3R-targeted compounds often also interact with D2 receptors (D2R). The purpose of this study was to compare the consequences of selective D2R or D3R antagonism on the behavioral effects of cocaine in mice, and to identify the neurobiological mechanisms underlying their modulatory effects.\n\nMethodsWe characterized the effects of selective D2R or D3R antagonism in mice on 1) basal and cocaine-induced locomotor activity, 2) presynaptic dopamine release and clearance in the nucleus accumbens using ex vivo fast scan cyclic voltammetry, and 3) dopamine-mediated signaling in D1-expressing and D2-expressing medium spiny neurons using ex vivo electrophysiology.\n\nResultsPretreatment with the selective D2R antagonist L-741,626 attenuated, while pretreatment with the selective D3R antagonist PG01037 enhanced, the locomotor-activating effects of acute and repeated cocaine administration. While both antagonists potentiated cocaine-induced increases in presynaptic DA release, D3R blockade uniquely facilitated DA-mediated excitation of D1-expressing medium spiny neurons in the nucleus accumbens.\n\nConclusionsSelective D3R antagonism potentiates the behavioral-stimulant effects of cocaine in mice, an effect that is in direct opposition to that produced by selective D2R antagonism or nonselective D2-like receptor antagonists, likely by facilitating D1-mediated excitation in the nucleus accumbens. These findings provide important insights into the neuropharmacological actions of D3R antagonists on mesolimbic dopamine neurotransmission.

neuroscience↗

bioRxiv2018

Levodopa and dopamine dynamics in Parkinson’s disease metabolomics

Parkinsons disease (PD) is a progressive neurological disorder caused by a combination of genetic and environmental factors. Metabolomics is a powerful tool that can be used to screen for potential biomarkers, exogenous toxicants, and metabolic network changes associated with disease states. Here, we used high-resolution metabolomics to compare over 10,000 plasma metabolic features from older adults with and without PD in an untargeted approach. We performed a network analysis that demonstrates that the presence of the PD drug levodopa influences variation observed between PD and control patients. Metabolome wide association studies and discrimination analysis identified significant differentiation in the metabolomics profile of older adults with and without PD. Notably, 15 metabolic features (ten of which we putatively identified) differed between PD and control adults with p < 0.05 and a corrected false discovery rate less than 20%. Furthermore, 13 metabolic networks were identified to be functionally different between PD and non-PD patients. Lastly, the dopaminergic toxic intermediate DOPAL differed between PD and non-PD populations, which supports the dopaminergic sequestration model of PD. These individual metabolites and metabolic networks have been implicated in past PD pathogenesis models, including the beta-carboline harmalol and the glycosphingolipid metabolism pathway including the ganglioside GM2. We recommend that future studies take into account the confounding effects of levodopa in metabolomic analyses of disease versus control patients, and encourage validation of several promising metabolic markers of PD.

neuroscience↗

bioRxiv2017

Increased Activity of Tyrosine Hydroxylase Leads to Elevated Amphetamine Response and Markers of Oxidative Stress in Transgenic Mice

In Parkinsons disease, noradrenergic cells of the locus coeruleus and dopamine cells within the nigrostriatal pathway undergo profound degeneration. Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the production of all catecholamines, including dopamine and noradrenaline, and is selectively expressed in the cells that produce these neurotransmitters. In vitro studies have previously shown that the TH-synthetic system can contribute to the formation of reactive oxygen species. In addition, animal models of dopamine mishandling demonstrated that free dopamine is neurotoxic. To examine how increased TH activity might influence catecholamine systems in vivo, we generated TH-overexpressing mice (TH-HI) with six total copies of the TH murine gene. A commensurate increase in TH mRNA produced a threefold increase in both total TH protein and phosphorylated TH levels. We found an increased rate of dopamine synthesis in both young and adult mice, reflected by the accumulation of L-DOPA following NSD-1015 administration, as well as elevated dopamine tissue content in young mice and an increased presence of dopamine metabolites at both ages. Adult mice show no difference in baseline locomotor behaviour compared to wildtype littermates, but a have potentiated response to amphetamine. In addition to elevated dopamine turnover in the striatum, TH-HI mice show reduced levels of glutathione and increased levels of cysteinylated catechols. These results indicate that a heightened level of active TH can produce oxidative stress, and may represent a source of toxicity that is specific to catecholamine cells, which are most vulnerable to degeneration in Parkinsons disease.

neuroscience↗